Nirali Vora, MD
Vascular Neurology · Stanford, CANPI 1578797460
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $4,714 with a category attached, or 63.6%. Portola Pharmaceuticals, LLC accounts for 69.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $3,258 and has fallen 94.8% since, to $171 in 2025.
Across 19 payments — averaging $248.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Portola Pharmaceuticals, LLC$3K
- Janssen Research & Development, LLC$1K
- AstraZeneca$21
Across 30 payments — averaging $10,864 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$262K
- E.r. Squibb & Sons, L.L.C.$64K
What the payments were for
- Speaking & faculty fees$3,00064%
- Travel & lodging$1,09523%
- Food & beverage$61913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Portola Pharmaceuticals, LLC | 8 | $3,258 |
| Janssen Research & Development, LLC | 10 | $1,435 |
| AstraZeneca | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$3,000
How this compares
$4,714 in reported general payments places this provider in the 70th percentile of 58 vascular neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 13 | $590 |
| Ezetimibe | 11 | $133 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Stanford
- Gregory AlbersStanford$415K
- Chitra VenkatasubramanianStanford$260K
- Maarten LansbergStanford$86K
- Sarah LeeStanford$35K
- Neeharika KrothapalliStanford$959
- Lironn KralerStanford$20
- Shuichi SuzukiArcadia$126K
- Royya ModirSan Diego$113K
- Muhammad TaqiPalm Springs$77K
- Ashish NandaFullerton$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.